Posts by: Ana Pena, PhD

Ana Pena, PhD

Ana holds a PhD in Biomedical Sciences from the Faculty of Medicine, University of Lisbon, Portugal. Her main contributions as a researcher were in molecular biology, parasitology and translational research. Currently, she is highly interested and working in innovation in healthcare and science communication.

November 19, 2018

FDA Grants Poseida’s P-BCMA-101 RMAT Status for Treatment of Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate, the Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of relapsed ... Read more

October 31, 2018

New Compound Safely Halts Advanced Myeloma Progression in Small Pilot Study

News

A new investigational compound targeting a central pathway in cancer development showed promising results in patients with relapsed or refractory multiple myeloma in a small Phase 1/2a pilot trial. ... Read more

July 30, 2018July 30, 2018

Urine Tests May Be Better Than Serum for Multiple Myeloma Screening, Study Suggests

News

Urine tests may be better than serum tests to diagnose multiple myeloma or its precursor conditions, because they can spot cases that would be missed by serum screenings, a ... Read more

July 9, 2018July 9, 2018

Twice‐weekly Ninlaro Combo Improves Outcomes in Newly Diagnosed Myeloma Patients, Trial Shows

News

Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple myeloma, although it’s likely more toxic than once-weekly Ninlaro, according to ... Read more

June 1, 2018

Pomalyst Triple Combo Delays Disease Progression in Relapsed or Refractory Myeloma Patients, Phase 3 Data Show

News

Adding Pomalyst (pomalidomide) to a combination of Velcade (bortezomib) and dexamethasone significantly extended the time until disease worsening or death in patients with relapsed or refractory multiple myeloma, updated Phase 3 ... Read more

May 16, 2018

Recruitment Open for Phase 2 Trial Aimed at Complete Eradication of Myeloma Cells

News

The University of Alabama at Birmingham (UAB) is recruiting patients with newly diagnosed multiple myeloma for a Phase 2 trial evaluating an innovative treatment approach with the goal of ... Read more

April 13, 2018April 13, 2018

Selinexor Gains FDA Fast Track Designation for Refractory Multiple Myeloma Patients

News

Selinexor, the lead oral therapy developed by Karyopharm Therapeutics, received Fast Track designation by the U.S. Food and Drug Administration (FDA), for the treatment of refractory multiple myeloma patients — those ... Read more

March 23, 2018March 23, 2018

SELLAS Vaccine More Than Doubles Time to Myeloma Progression, Phase 2 Trial Shows

News

SELLAS Life Sciences’ Galinpepimut-S vaccine more than doubles the time it takes for high-risk multiple myeloma patients’ cancer to worsen, a Phase 2 clinical trial shows. Myeloma expert Guenther Koehne presented the results at the Annual ... Read more

March 2, 2018

Mouse Study Finds Potential Targets to Minimize Risks of Stem Cell Transplants

News

Immune factors that drive donor T-cells to cause graft-versus-host disease (GVHD) have been found by researchers whose discovery may offer new opportunities for therapeutic targets to minimize the risks of ... Read more

Pin It on Pinterest